# Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

> **NCT03356054** · PHASE1,PHASE2 · RECRUITING · sponsor: **Stichting Hemato-Oncologie voor Volwassenen Nederland** · enrollment: 37 (estimated)

## Conditions studied

- DLBCL

## Interventions

- **COMBINATION_PRODUCT:** R-DHAP
- **DRUG:** Brentuximab Vedotin

## Key facts

- **NCT ID:** NCT03356054
- **Lead sponsor:** Stichting Hemato-Oncologie voor Volwassenen Nederland
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-03-05
- **Primary completion:** 2023-01
- **Final completion:** 2027-02
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2020-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03356054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03356054, "Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03356054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*